Industries > Pharma > Top 25 Biosimilar Drug Manufacturers 2019

Top 25 Biosimilar Drug Manufacturers 2019

Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies

PUBLISHED: 17 April 2019
PAGES: 220
PRODUCT CODE: PHA0414
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0414 Categories: , Tags: , , ,

Visiongain forecasts that the biosimilar drugs market will grow with a CAGR of 40% from 2018 to 2028. Growth is expected to be rapid during the first-half of the forecasted period due to the patent cliff from years 2012-2019, which will see the patent expiry of many of the most popular biologics in the world. The opening of the US market due to clearer defined guideline regarding biosimilars will lead to greater penetration of biosimilars in this lucrative market, which will help the rapid growth and development of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 220-page report you will receive 117 charts– all unavailable elsewhere.

The 220-page report provides clear detailed insight into the top 25 biosimilar drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

• Discussion and overview of the leading biologic and biosimilar products, covering:
• Humira
• Remicade
• Enbrel
• Aranesp
• Rituxan
• Adalimumab biosimilars
• Infliximab biosimilars
• Etanercept biosimilars
• Darbepoetin Alpha biosimilars
• Rituximab biosimilars

• Profiles of leading biosimilar companies based in the US, Western Europe and Israel:
• Hospira
• Mylan
• Sandoz
• STADA Arzneimittel
• Teva Pharmaceutical Industries
• Other companies in these regions

• Profiles of leading biosimilar companies based in China:
• 3SBio
• Beijing ShuangLu Pharmaceuticals
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceuticals
• Tonghua Dongbao
• Other companies in China

• Profiles of leading biosimilar companies based in India:
• Biocon
• Dr. Reddy’s Laboratories
• Intas Biopharmaceuticals.
• Ranbaxy
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila
• Other companies in China

• Profiles of leading biosimilar companies based in Latin America:
• Probiomed
• Biosidus
• Amega Biotech
• Other companies in Latin America

• Profiles of leading biosimilar companies based in the rest of the world:
• Celltrion
• LG Life Sciences
• Dong-A
• Bioton
• Biocad
• Other companies in the rest of the world

Top 25 Biosimilar Drug Manufacturers 2019

• The report provides information and discussion on:
• Company overview & analysis
• Biosimilars Products
• Future Outlook
• Technologies and activities
• R&D Pipelines

• Qualitative analysis: a SWOT and STEP analysis of the biosimilars market. Discussion on factors that drive and restrain the biosimilars market.

• Key questions answered by this report:
• What are its drivers and restraints of the biosimilar drugs market?
• What are the leading biosimilar products in the market and which companies manufacture them?
• Who are the leading biosimilars companies?
• What are their products, developmental candidates and therapeutic applications?
• What is the status of the clinical trials they are undergoing?
• What are the latest news and developments from those companies?
• What other biopharmaceutical companies seem promising within the regions we analyse, having potential to succeed in biosimilar drug development, production and marketing?
• What are leading companies’ biosimilar products and what candidates are in their R&D pipelines?
• What are the social, technological, economic and political forces affecting the world biosimilars market?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Biosimilar Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Biosimilar Drug Manufacturers 2019: Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 25 Biosimilar Drug Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 25 Biosimilar Drug Manufacturers 2019


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category